Login to Your Account



Patents Trump NCE Status

Amarin Gains Approval, Next Step: Holding Off Generics

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, August 6, 2012

Amarin Corp. plc got a green light from the FDA to market its triglyceride-lowering drug Vascepa (icosapent ethyl) last month. Now the biotech needs to give a red light to potential generic competitors. 

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription